On August 4, 2026, the Sullian Summit 2026 was grandly held at Shangri-La Shanghai Jing'an Hotel. Coinciding with the event, a celebration dinner was held to mark the 65th anniversary of Sullian Global and the 20th anniversary of the Sullian Summit in China. The 2026 Sullian Global Awards and Chinese Awards were announced at this event.
The event attracted numerous guests from various fields, including leaders of industry associations, experts from academic societies, representatives from investment and financing circles, executives of leading enterprises in the industry, media professionals, and scholars from higher education institutions. Everyone gathered together to celebrate this occasion.
Regarding Sullian Best Practices Awards
The Sullian Growth, Innovation, and Leadership Best Practices Awards (referred to as GIL Awards) aim to recognize outstanding companies that have made significant contributions and achieved leadership positions in various industries. After nearly 30 years of development worldwide, the authority and fairness of these awards have been widely recognized by the investment and financial industries as well as within the industry. So far, over 5,000 excellent companies have been honored globally.
The GIL Awards cover more than 20 countries and regions, directly connecting with the world’s top 1,000 companies and industry leaders. Award information is disseminated in multiple languages through over 100 global media outlets, providing strong brand support for companies' internationalization efforts.
2026 marks the 65th anniversary of Sullian Global. During this year, Sullian China continuously studied numerous entrepreneurial and investment success cases in high-tech and strategic emerging industries. Through objective analysis and comprehensive evaluation, the innovation capabilities, business models, founding teams, technical abilities, and future prospects of participating companies were assessed. Together with a professional judging committee, many outstanding biotech leaders were selected.
Award ceremony at the event
Medical companies that received the 2026 Sullian GIL Global Award include: Beijing Gene Qiming Biotechnology Co., Ltd., Chengdu Shibekang Biopharmaceutical Technology Co., Ltd., Guangzhou Paizhen Biotechnology Co., Ltd., Hangzhou Nuanxinjia Electronic Technology Co., Ltd., Hangzhou Xuzhi Shi Technology Co., Ltd., Jiehua Biotechnology (Qingdao) Co., Ltd., Jilin Jumei Biotech Co., Ltd.,Lingke Pharmaceutical Co., Ltd.(Zhejiang) Co., Ltd., US BHF Reproductive Center, Puluo Pharmaceutical Co., Ltd., Shanghai Junsei Biotech Co., Ltd., Shanghai Yinghe Yimai Intelligent Technology Co., Ltd., Shenzhen Saiqiao Biotech Innovation Technology Co., Ltd.
Prof. Vinod K. Aarwal, Global Chief Economist of Sullian, Distinguished Professor at UC Berkeley, and Director of APEC Research Center; Dr. Hu Jiguang, Member of Sullian Growth Strategy Expert Committee, Vice President of Morgan Stanley ChinaBeijing Gene Qiming Biotechnology Co., Ltd.Award ceremony
Beijing Gene Qiming Biotechnology Co., Ltd. is the annual company in the field of iNKT cell drugs worldwide.Established in 2015 in Beijing, Beijing Gene Qiming Biotechnology Co., Ltd. is the only company worldwide with a full spectrum of operationsiNKT cellsservices. The company has established a complete research-production-clinical system, built a leading global iNKT cell pilot production platform, and holds exclusive and self-controlled core technologies for cell expansion and subpopulation regulation. It has won several international innovation awards.
As a national high-tech, specialized and innovative enterprise, it led the development of the first group standard for iNKT cell industry. It has obtained 7 NMPA registration clinical approvals, covering areas such as cancer, autoimmunity, and severe respiratory diseases. It was the first in the world to verify the efficacy of iNKT cell therapy for liver cancer, and many products have achieved global breakthroughs. The company has completed an industrial transition from zero to one in the iNKT cell field, reshaping the global cell therapy industry landscape.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of Sullian; Meng Yi, Executive Chairman of Sullian Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking ChinaChengdu Shibekang Biopharmaceutical Technology Co., Ltd.Award ceremony.
Chengdu Shibekang Biopharmaceutical Technology Co., Ltd. is the annual company worldwidein cardiovascular and respiratory new drug research and development.and respiratory new drug research and development.Shibekang adheres to the mission of "giving benefits to all, enhancing health," and the values of "people-oriented, innovation-driven, and innovation-first." Guided by clinical needs, it maintains a differentiated research and development strategy, focuses on cardiovascular and respiratory diseases, and aims to become a world-class leader in differentiated innovation in new drugs, developing better medicines to benefit people and protect human health.
Prof. Vinod K. Aggarwal, Global Chief Economist of Sullian, Distinguished Professor at UC Berkeley, Director of APEC Research Center; Dr. Liu Jun, Chairman of JULI Technology, Member of Sullian Specialized Committee on Specialized and Innovative Enterprises, Vice President of HSBC Global Banking ChinaGuangzhou Paizhen Biotechnology Co., Ltd.Award ceremony.
Guangzhou Paizhen Biotechnology Co., Ltd. is a technology innovation leading enterprise in the field of gene therapy CRDMO worldwide.Founded in 2014, Paizhen Biology aims to make gene therapy affordable for ordinary people. By using advanced vector technology and one-stop services, it accelerates the adoption of gene therapy, a transformative treatment, around the world. Facing the huge clinical potential of AAV vector therapy but high costs and technical barriers in traditional methods, Paizhen focuses on driving AAV production andCGTindustrial transformation in this field, making high-quality, large-scale, and cost-effective production possible.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of Sullian; Meng Yi, Executive Chairman of Sullian Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking ChinaHangzhou Nuanxinjia Electronic Technology Co., Ltd.Award ceremony
Hangzhou Nuanxinjia Electronic Technology Co., Ltd. is the annual company worldwidein visual brain-computer interfacefield.Nuanxinjia Technology has a 2,000-square-meter GMP workshop with high precision medical device production capabilities. Its products cover multiple lines such as visual brain-computer interfaces and neural regulation, and it has established several R&D subsidiaries at home and abroad, forming a global collaborative innovation network. In May 2026, the company successfully completed a Chinese GCP clinical trial, achieving a visual reconstruction breakthrough where patients can recognize complex letters the day after setup, potentially helping them regain functional vision and independent living. As a founding member of the National Brain-Computer Standard Committee, Nuanxinjia has participated in the formulation of brain-computer interface national standards led by ministries such as the National Health Commission, Ministry of Industry and Information Technology, and the State Administration for Market Regulation, contributing to the rapid development of China’s brain-computer interface industry.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of Sullian; Meng Yi, Executive Chairman of Sullian Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking ChinaHangzhou Xuzhi Shi Technology Co., Ltd.Award ceremony.
Hangzhou Xuzhi Shi Technology Co., Ltd. (NEUREAL) is a national specialized and innovative "little giant" enterprise focused on non-invasive brain-computer interfaces (BCI).With "emotional brain-computer" as its technical direction, the company focuses on emotional and cognitive decoding, applying cutting-edge technologies such as AI, brain-computer interfaces, VR, DCBT, and tDCS in clinical settings, serving individuals with brain disorders such as depression, ADHD, autism, and cognitive decline. Its services cover hospital clinical settings, adolescent psychological intervention, and home brain health. By decoding emotions and cognition, the company improves brain health.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of Sullian; Meng Yi, Executive Chairman of Sullian Growth Strategy Expert Committee, former General Manager and Vice President of HSBC Global Banking ChinaJiehua Biotechnology (Qingdao) Co., Ltd.Award ceremony
Jiehua Biotechnology (Qingdao) Co., Ltd. is a technology innovation leading enterprise in the field of large molecular new drugs worldwide.With over twenty years of research and development experience in biological new drug manufacturing, Jiehua Biotechnology has established a complete biopharmaceutical technology chain from laboratory-scale production of novel large molecules to large-scale industrial production, possessing the capability to continuously innovate and produce original biological large molecules.
Dr. Wang Xin, Global Senior Vice President, Asia-Pacific Co-Chairman, Chairman of China; Dr. Bi Shunjie, Head of Sullian Professional Institutions, Enterprise Services Partner in Greater China of Ernst & YoungJilin Jumei Biotech Co., Ltd.Award ceremony.
Jilin Jumei Biotech Co., Ltd. is a leading enterprise worldwide in humanized recombinant full-spectrum collagen anti-aging products.Established in September 2024, Jilin Jumei Biotech is the first Asian company to achieve large-scale production of humanized elastic protein. Its main products include microbial proteins, amino acid-based water-soluble fertilizers, and other bio-fermentation products. Microbial proteins are efficient, low-cost, sustainable, and healthier, aligning with national and local industrial development policies.
Prof. Vinod K. Aggarwal, Global President and Managing Partner, Global Board Executive Director of Sullian; Prof. Wang Yu, Chairman of China Hepatitis Prevention and Control Foundation, former Director of China Center for Disease Control and PreventionLingke Pharmaceutical (Zhejiang) Co., Ltd.Award ceremony.
Lingke Pharmaceutical (Zhejiang) Co., Ltd. is the annual company worldwide in the field of autoimmune and inflammatory small molecules.Through developing innovative therapies, Lingke Pharmaceutical addresses unmet clinical needs. It aims to benefit global patients through differentiated innovative therapies. So far, Lingke has developed several self-developed first-class clinical new drugs and has conducted multiple clinical trials globally, either independently or in collaboration with international partners.
Dr. Wang Xin, Global Senior Vice President, Asia-Pacific Co-Chairman, Chairman of China; Yang Guoping, Chairman of Mass Transit GroupUS BHF Reproductive CenterAward ceremony.
US BHF Reproductive Center (Beverly Hills Fertility) received the Sullian Global Assisted Reproduction Market Leadership Award.As one of the few international reproductive centers in California, BHF is composed of renowned reproductive endocrinologists, infertility experts, embryology experts, and laboratory experts, with an average tenure of nearly 20 years.
BHF has laboratories certified under CLIA and CAP, and has passed the TJC certification, which is a high-level review of medical quality and service standards in the United States. BHF has a high egg revival rate of 97%, a high fertilization rate, and pregnancy success rates for patients of all ages, exceeding the world’s top laboratory benchmarks defined by the Vienna Consensus.
BHF adheres to the concept of personalized reproductive care, integrating cutting-edge genetic science, advanced embryo laboratory technology, and big data analysis to optimize customized reproductive medicine. It has become a designated partner hospital for women’s fertility services for many Fortune 500 companies.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of Sullian; Prof. Vinod K. Aggarwal, Chairman of China Hepatitis Prevention and Control Foundation, former Director of China Center for Disease Control and PreventionPuluo Pharmaceutical Co., Ltd.Award ceremony
Puluo Pharmaceutical Co., Ltd. (000739.SZ) received the 2026 Sullian GIL “Global CDMO Annual Company Award.”The company specializes in integrated services for specialty active pharmaceutical ingredients and small molecule CDMOs. With seven active pharmaceutical ingredient production bases (including chemical synthesis and bi fermentation), two formulation factories, and products in advantageous treatment areas such as cardiovascular, anti-infection, mental health, and anti-tumor, it has built a continuous, automated, digital, and intelligent pharmaceutical manufacturing and process development platform. Its quality system has passed official audits and inspections by China NMPA, US FDA, EUEMA/EDQM, and Japan PMDA, ensuring compliant market supply and full traceability across the entire chain. It continues to provide one-stop research and manufacturing services to domestic and international innovative pharmaceutical companies, CROs, and formulation providers.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of Sullian; Prof. Vinod K. Aggarwal, Chairman of China Hepatitis Prevention and Control Foundation, former Director of China Center for Disease Control and PreventionShanghai Junsei Biotech Co., Ltd.Award ceremony
Shanghai Junsei Biotech Co., Ltd. is the annual company worldwide in the field of solid tumor cell therapy.With three proprietary technology platforms: DeepTIL™ cell expansion platform, NovaGMP™ gene modification technology platform, and RiverTIL™ endogenous TIL platform, the company enhances product efficacy and safety from the source, significantly reducing production and comprehensive treatment costs, and improving the accessibility of TIL therapy. Focusing on highly prevalent tumors and refractory tumors, the company has developed a series of first-in-class or best-in-class autologous natural TIL and gene-modified TIL products, covering early adjuvant treatment to late-stage treatment, across multiple disease stages and treatment scenarios.
Aroop Zutshi, Global President and Managing Partner, Global Board Executive Director of Sullian; Prof. Vinod K. Aggarwal, Chairman of China Hepatitis Prevention and Control Foundation, former Director of China Center for Disease Control and PreventionShanghai Yinghe Yimai Intelligent Technology Co., Ltd.Award ceremony
Shanghai Yinghe Yimai Intelligent Technology Co., Ltd. is the annual company worldwide in the field of medical imaging AGI.The company has deep medical and technical expertise. Its founding team members are top domestic and North American imaging medicine experts and big data & artificial intelligence experts, with rich management and research experience in imaging medicine, big data, and AI product development.
Based on its own globally leading cross-modal, full-process “Yinghe Miyu®” medical imaging base large model, the company creates full-link imaging intelligent solutions, multi-modal agents (Agents), doctor digital duplicates Al systems, and high-value medical imaging asset management platforms. By leveraging full-domain AI capabilities, it enhances clinical diagnosis and hospital management, redefines medical work efficiency, promotes digital, precise, and systematic upgrades in the medical industry, and builds the next-generation smart medical imaging AI ecosystem. In the future, it will expand its business into global markets.
Dr. Wang Xin, Global Senior Vice President, Asia-Pacific Co-Chairman, Chairman of China; Yang Guoping, Chairman of Mass Transit GroupShenzhen Saiqiao Biotech Innovation Technology Co., Ltd.Award ceremony.
Shenzhen Saiqiao Biotech Innovation Technology Co., Ltd. is a technology innovation leading enterprise worldwide in the field of CGT industry empowerment.The core team has been responsible for major national biInstrumentation projects. With over 10 years of experience in instrument engineering and biological-related technologies, it is one of the earliest specialized teams in China focusing on cell processing and automated equipment. With the vision of “no disease that cannot be treated,” Saiqiao focuses on the industry characteristic of “process being product, tools being process” in cell therapy, as well as the core industry pain point of “cannot deliver, cannot afford.” It works closely with industry customers to become one of the top three cell therapy tool platforms worldwide, covering early research, clinical, and commercial stages with complete independent intellectual property rights.
Medical companies that received the 2026 Sullian GIL China Award include: Fuxiang Co., Ltd., Pukang Biotech Technology (Shanghai) Co., Ltd., Shenzhen Zeyi Cell Therapy Group.
Georgia Edell, Global Chief Analyst of Sullian Asia; Diego Shimizu, Asian Analyst of SullianFuxiang Co., Ltd.Award ceremony.
Fuxiang Co., Ltd. (300497.SZ) is a market leading enterprise in the field of synthetic biobiotics in China.Fuxiang Co., Ltd. has actively expanded into the field of synthetic biology in response to the global biotech development trend. It is now the first Asian company to achieve large-scale industrialization of filamentous fungal proteins. Its main products include microbial proteins, amino acid-based water-soluble fertilizers, and other bio-fermentation products. Microbial proteins are efficient, low-cost, sustainable, and healthier, aligning with national and local industrial development policies.
Georgia Edell, Global Chief Analyst of Sullian Asia; Jihun Kang (Will), Asian Analyst of SullianFukang Biotechnology (Shanghai) Co., Ltd.Frost & Sullivan Awards Frost & Sullivan Frost & Sullivan China LeadLeo Research Institute LeadLeo
Fukang Biotechnology (Shanghai) Co., Ltd. is a product innovation company in the field of cancer immunotherapy drugs in ChinaFrost & Sullivan focuses on developing cutting-edge treatment methods for cancer, while also advancing innovative drug research for viruses and age-related diseases. The company aims to provide multi-line treatment options and serve a broad patient population to drive rapid revenue growth. The company has adopted the "One Drug, Multiple Indications" (PIP) model in research, designing a single drug to cover multiple therapeutic uses. This approach has successfully expanded the new indications of some candidate drugs, and will further extend to common solid tumors such as respiratory, gastrointestinal, and urological cancers.
Frost & Sullivan Global Executive Board Member and Chief AI Architect Subhranshu Shekhar Das, along with Frost & Sullivan China Managing Partner and President Wang ChenhuiShenzhen Zeyi Cell Therapy GroupFrost & Sullivan Awards Frost & Sullivan Frost & Sullivan China LeadLeo Research Institute LeadLeo
Frost & Sullivan China is a market-leading company in the field of long-life medical services.Frost & Sullivan China, with the core objective of enhancing healthy lifespan, has joined forces with Nobel laureates, academicians, and medical experts from home and abroad to launch the “Eternal Life Ark” program. The initiative continues to explore scientific approaches that enable people to live longer, healthier, and more fulfilling lives, helping humans enjoy a happy life until old age.
Based on Cell Technology as its core engine, it integrates life genomics, functional assessment, chronic disease management, and clinical translation, connecting research, healthcare, and health management to establish a full-lifecycle longevity medicine system covering risk identification, precise evaluation, proactive intervention, and long-term management, thereby advancing health services from treating existing diseases to proactive health promotion, comprehensive management, and increased healthy lifespan.
More exciting moments from the event
